Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.646333 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.646333 33995364!8121250!33995364     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 646333 Nephropedia Template TP {{tp|p=33995364|t=2021. Cellular Immune Response to COVID-19 and Potential Immune Modulators |pdf=|usr=}}{{33995364}} gab.com Text Cellular Immune Response to COVID-19 and Potential Immune Modulators JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33995364 #FOAvip Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Droplets and contacts serve as the main route of transmission of SARS-CoV-2. The characteristic of the disease is rather heterogeneous, ranging from no symptoms to critical illness. The factors associated with the outcome of COVID-19 have not been completely characterized to date. Inspired by previous studies on the relevance of infectious diseases, viral and host factors related to clinical outcomes have been identified. The severity of COVID-19 is mainly related to host factors, especially cellular immune responses in patients. Patients with mild COVID-19 and improved patients with severe COVID-19 exhibit a normal immune response to effectively eliminate the virus. The immune response in patients with fatal severe COVID-19 includes three stages: normal or hypofunction, hyperactivation, and anergy. Eventually, the patients were unable to resist viral infection and died. Based on our understanding of the kinetics of immune responses during COVID-19, we suggest that type I interferon (IFN) could be administered to patients with severe COVID-19 in the hypofunctional stage, intravenous immunoglobulin (IVIG) and glucocorticoid therapy could be administered in the immune hyperactivation stage. In addition, low molecular weight heparin (LMWH) anticoagulation therapy and anti-infective therapy with antibiotics are recommended in the hyperactivation stage. Twit Text FOAVip Cellular Immune Response to COVID-19 and Potential Immune Modulators ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33995364 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33995364 #FOAvip English Wikipedia <ref>{{Cite pmid|33995364}}</ref> Cellular Immune Response to COVID-19 and Potential Immune Modulators #MMPMID33995364 Zhou X; Ye Q Front Immunol 2021[]; 12 (ä): 646333 PMID33995364show ga Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Droplets and contacts serve as the main route of transmission of SARS-CoV-2. The characteristic of the disease is rather heterogeneous, ranging from no symptoms to critical illness. The factors associated with the outcome of COVID-19 have not been completely characterized to date. Inspired by previous studies on the relevance of infectious diseases, viral and host factors related to clinical outcomes have been identified. The severity of COVID-19 is mainly related to host factors, especially cellular immune responses in patients. Patients with mild COVID-19 and improved patients with severe COVID-19 exhibit a normal immune response to effectively eliminate the virus. The immune response in patients with fatal severe COVID-19 includes three stages: normal or hypofunction, hyperactivation, and anergy. Eventually, the patients were unable to resist viral infection and died. Based on our understanding of the kinetics of immune responses during COVID-19, we suggest that type I interferon (IFN) could be administered to patients with severe COVID-19 in the hypofunctional stage, intravenous immunoglobulin (IVIG) and glucocorticoid therapy could be administered in the immune hyperactivation stage. In addition, low molecular weight heparin (LMWH) anticoagulation therapy and anti-infective therapy with antibiotics are recommended in the hyperactivation stage. |*COVID-19 Drug Treatment[MESH] |*COVID-19/immunology/mortality[MESH] |Glucocorticoids/therapeutic use[MESH] |Heparin, Low-Molecular-Weight/therapeutic use[MESH] |Humans[MESH] |Immunity, Cellular/*drug effects[MESH] |Immunoglobulins, Intravenous/therapeutic use[MESH] |Immunologic Factors/*therapeutic use[MESH] |Interferon Type I/therapeutic use[MESH]Cellular Immune Response to COVID-19 and Potential Immune Modulators (epmc).pdf DeepDyve Pubget Overpricing